Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06536465 · ClinicalTrials.gov registry record · Phase 2
The Clostridioides Difficile Trial of REC-3964
A Phase 2 study, sponsored by Recursion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06536465: Clinical Trial Phase 2 study, sponsored by Recursion Pharmaceuticals.
NCT06536465 is a Phase 2 study that was terminated before completion, run by Recursion Pharmaceuticals. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06536465, a Phase 2 study, was terminated before completion, sponsored by Recursion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
Primary Outcome
Recurrent CDI was defined as a new episode of CDI associated with a new positive Clostridioides difficile stool toxin or requirement for additional CDI treatment during the 8-week Follow-up Period after cure of preceding CDI with initial curative treatment.
Interventions
- DRUG REC-3964
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 2 |
Why NCT06536465 stopped before completion
NCT06536465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which REC-3964 is the first listed.
NCT06536465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06536465 about?
NCT06536465 is a clinical study titled "The Clostridioides Difficile Trial of REC-3964". This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
What is the current status of trial NCT06536465?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2024-10-14. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT06536465?
The interventions under investigation include: REC-3964 (DRUG).
Who is sponsoring clinical trial NCT06536465?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06536465's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI